CPA
AVBP icon

Capital Performance Advisors’s ArriVent BioPharma AVBP Stock Holding History

Capital Performance Advisors’s Portfolio AVBP Stock Details AVBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-67
Closed -$1.57K – 2776
2024
Q3 		$1.57K Buy
+67
New +$1.52K ﹤0.01% 1679

Other funds holding AVBP

HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
IAM
Infinitum Asset Management Fort Lauderdale, Florida $801M AUM 8.83% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
GCGM
General Catalyst Group Management Cambridge, Massachusetts $184M AUM 50.45% 1-Year Est. Return

Capital Performance Advisors's AVBP Position: Q4 2024 in Review

Capital Performance Advisors sold out of ArriVent BioPharma (AVBP) in Q4 2024, closing a stake of 67 shares — an estimated $1.57K sold.

Capital Performance Advisors first reported a position in AVBP in Q3 2024 and held it in 1 quarter. The position peaked at $1.57K in Q3 2024. 80 funds tracked by Wall St. Rank hold AVBP as of Q4 2024.

  • Capital Performance Advisors reported no remaining ArriVent BioPharma position as of Q4 2024 after selling out during the quarter.
  • Capital Performance Advisors sold 67 ArriVent BioPharma shares in Q4 2024, an estimated $1.57K.
  • Capital Performance Advisors first reported a position in ArriVent BioPharma in Q3 2024 and held it in 1 quarter.
  • Capital Performance Advisors's ArriVent BioPharma position peaked at $1.57K in Q3 2024.
  • 80 funds tracked by Wall St. Rank held ArriVent BioPharma as of Q4 2024.

Based on Capital Performance Advisors's 13F filing for Q4 2024, filed 31 Jan 2025.